Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.83 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12770255 | 0.91 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12781952 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL207789 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29837082 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13626079 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17034642 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14648451 | 0.89 | SLC5A2 (0.85) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18265042 | 0.89 | SLC5A2 (0.85) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12781996 | 0.86 | SLC5A2 (0.82) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12781950 | 0.85 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143021-A1 | METHOD FOR TREATING AND PREVENTING KIDNEY STONES EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-26 | — | — | WO | disclosed |